Registration Options

Workshop Date: 3/1/2023

CVD Risk Management Workshop RegistrationMembersNon-members
Virtual Pre-Meeting Workshop: CVD Risk Management$110$120
Virtual Pre-Meeting Workshop: CVD Risk Management Fellow/Resident$80$100
Virtual Pre-Meeting Workshop: CVD Risk Management Student$50$70

Save $20 when you bundle this virtual workshop with your in-person AAPP 2023 registration.

Session Time

Date: Wednesday, 03/01/2023

Time: 1:00 PM

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional providing comprehensive medication management for individuals living with psychiatric disorders, we invite you to participate in this course.

Session Summary

[Virtual Workshop]

Individuals with severe mental illness (SMI), such as schizophrenia, bipolar disorder and depression, have an elevated risk of cardiovascular disease (CVD). In addition to the increased prevalence of modifiable risk factors in these populations, many of the medications used in disease management have been linked to weight gain and/or worsening of metabolic cardiovascular risks. Pharmacists are often an underutilized health care resource despite their medication expertise and accessibility. As frontline clinicians, psychiatric pharmacists are trained in the detection and ongoing monitoring of various cardiovascular comorbidities, and are frequently the first to identify such problems. When pharmacists partner with prescribers they are able to take the lead in developing treatment plans, communicating with patients, improving adherence, monitoring patients, identifying treatment options, and performing tasks to alleviate prescriber burden.

This workshop will demonstrate different practice settings where psychiatric pharmacists partner with prescribers to provide collaborative care for metabolic disorders in patients with comorbid mental illness. Participants will leave with updated knowledge of current practice standards and treatment strategies for managing comorbid CVD. Furthermore, participants will gain a better understanding of how to incorporate this knowledge into routine practice through the practical application in real-life case scenarios.

Agenda (CST)

  • 1:00-1:10 PM: Welcome and Introductions
  • 1:10-1:35 PM: Discussion of key guidelines and assessment tools 
  • 1:35-1:45 PM: Small group evaluation of case (focus on guideline application and determining if intervention is warranted for the primary prevention of CVD while considering psychiatric illness) 
  • 1:45-2:00 PM: Reporting results to large group 
  • 2:00-2:10 PM: Break
  • 2:10-2:35 PM: Discussion of standard treatment approaches and clinical pearls for drug selection in secondary prevention CVD patients
  • 2:35-2:45 PM: Small group evaluation of case (focus on appropriate treatment selection and level of intervention while considering psychiatric illness in a secondary prevention CVD patient) 
  • 2:45-3:00 PM: Reporting results to large group 
  • 3:00-3:10 PM: Break
  • 3:10-3:35 PM: Discussion of optimization and ongoing monitoring in vulnerable patient populations 
  • 3:35-3:45 PM: Small group evaluation of case (focus on optimizing treatment and therapeutic goals in vulnerable populations while considering psychiatric illness) 
  • 3:45-4:00 PM: Reporting results to large group 
  • 4:00-4:15 PM: Q&A

Course Requirements

To receive ACPE credit for this session, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor.
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information and Disclosures

Sarah Anderson PharmD, BCACP, BCPS, FASHP, FCCP

View biographical information and disclosures

Learning Objectives

  1. Review key recommendations from essential guidelines for the management of common cardiovascular diseases (CVDs).
  2. Apply various risk assessment tools to determine which patients require intervention.
  3. Describe current pharmacologic approaches for the management of CVD in a patient with mental illness.
  4. Identify strategies to achieve optimal outcomes in patients with CVD and mental illness.
  5. Select an appropriate monitoring plan for a patient with CVD to determine if treatment goals are being met.

Continuing Education Credit and Disclosures

Workshop Date: 3/1/2023
ACPE Contact Hours: 3
ACPE Number: 0284-0000-23-001-L01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

25 Years!